- Home
- HQH vs QURE Comparison
HQH vs QURE Comparison
Compare HQH & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQH
- QURE
- Stock Information
- Founded
- HQH 1986
- QURE 1998
- Country
- HQH United States
- QURE Netherlands
- Employees
- HQH N/A
- QURE N/A
- Industry
- HQH Finance Companies
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- HQH Finance
- QURE Health Care
- Exchange
- HQH Nasdaq
- QURE Nasdaq
- Market Cap
- HQH 839.2M
- QURE 725.4M
- IPO Year
- HQH N/A
- QURE 2007
- Fundamental
- Price
- HQH $16.35
- QURE $15.70
- Analyst Decision
- HQH
- QURE Strong Buy
- Analyst Count
- HQH 0
- QURE 10
- Target Price
- HQH N/A
- QURE $36.90
- AVG Volume (30 Days)
- HQH 183.8K
- QURE 1.1M
- Earning Date
- HQH 01-01-0001
- QURE 07-29-2025
- Dividend Yield
- HQH 11.56%
- QURE N/A
- EPS Growth
- HQH N/A
- QURE N/A
- EPS
- HQH 1.09
- QURE N/A
- Revenue
- HQH N/A
- QURE $14,337,000.00
- Revenue This Year
- HQH N/A
- QURE N/A
- Revenue Next Year
- HQH N/A
- QURE $278.91
- P/E Ratio
- HQH $15.24
- QURE N/A
- Revenue Growth
- HQH N/A
- QURE N/A
- 52 Week Low
- HQH $14.31
- QURE $4.45
- 52 Week High
- HQH $17.94
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- HQH 55.79
- QURE 59.17
- Support Level
- HQH $16.57
- QURE $14.70
- Resistance Level
- HQH $16.90
- QURE $16.66
- Average True Range (ATR)
- HQH 0.22
- QURE 0.80
- MACD
- HQH 0.07
- QURE 0.17
- Stochastic Oscillator
- HQH 60.07
- QURE 74.54
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.